Joining three teams backed by a total of $75 million, MIT researchers will tackle some of cancer’s toughest challenges.

Whitehead Institute Member Jonathan Weissman and collaborators developed a tool to reconstruct human cell family trees, revealing how blood cell production changes in old age.

Team-based targeted projects, multi-mentor fellowships ensure that scientists studying social cognition, behavior, and autism integrate multiple perspectives and approaches to pressing questions.

MIT and MGH researchers design a local, gel-based drug-delivery platform that may provoke a system-wide immune response to metastatic tumors.

A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease pathology, preserving neurons, and improving cognition in preclinical tests.

The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.

In addition to turning on genes involved in cell defense, the STING protein also acts as an ion channel, allowing it to control a wide variety of immune responses.

SMART researchers find the enzyne RlmN, which directly senses chemical and environmental stresses, can be targeted in drug development.

MIT researchers characterize gene expression patterns for 22,500 brain vascular cells across 428 donors, revealing insights for Alzheimer’s onset and potential treatments.

Aided by machine learning, scientists are working to develop a vaccine that would be effective against all SARS-Cov-2 strains.